Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial

Human Lactoferrin ELISA Kit from Innovative Research was used in the following study:

Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial

Firdausi Qadri PhD, Marjahan Akhtar PhD, Taufiqur R Bhuiyan PhD, Mohiul I Chowdhury MD, Tasnuva Ahmed MSc, Tanzeem A RafiqueMSc, Arifuzzaman Khan MBBS, Sadia I ARahman MSca, Farhana Khanam, Phila Anna Lundgren PhD, Gudrun Wiklund BSc, Joanna Kaim MSc, Madeleine Löfstrand BSc, Nils Carlin PhD, A Louis Bourgeois PhD, Nicole Maier PhD, Alan Fix MD, Thomas Wierzba PhD, Richard Walker PhD, Prof Ann-Mari Svennerholm MD

The Lancet Infectious Diseases
February 2020,

“…Enterotoxigenic Escherichia coli causes diarrhoea, leading to substantial mortality and morbidity in children, but no specific vaccine exists. This trial tested an oral, inactivated, enterotoxigenic E coli vaccine (ETVAX), which has been previously shown to be safe and highly immuongenic in Swedish and Bangladeshi adults. We tested the safety and immunogenicity of ETVAX, consisting of four E coli strains overexpressing the most prevalent colonisation factors (CFA/I, CS3, CS5, and CS6) and a toxoid (LCTBA) administered with or without a double-mutant heat-labile enterotoxin (dmLT) as an adjuvant, in Bangladeshi children... Stool specimens from infants were analysed for lactoferrin concentrations (Innovative Research Kit, Peary Court Novi, MI, USA) to exclude that responses were caused by breast milk contamination…”

Related products available from Innovative Research also include:

• Human Lactoferrin ELISA Kit
• Single Donor Human Breast Milk
• Single Donor Human Pediatric Fecal Matter
• Human Intelectin-1 (Omentin) ELISA Kit
• Single Donor Human Pediatric Serum